R-Pharm - Targeting IL-6 ligand - exploring a novel treatment option with a focus on olokizumab

Industry room 3
Satellite Symposia
03 June 2021 08:15 - 09:45

Learning Objectives:

  • Understand IL-6 signaling pathway and differentiate modes of action of various IL-6 inhibitors
  • Evaluate the scientific evidence of direct IL-6 inhibition in patients with moderately to severely active rheumatoid arthritis (efficacy, safety and tolerability based on global phase III studies)
  • Address the problem of ‘difficult to treat’ patients in RA: current approach and potential strategies
  • Reflect on the modern ways of RA management (EULAR guidelines in clinical practice)


Chair(s) of the session

Prof. Dr. Josef S. Smolen, Austria


Title Time Calendar .ics
Welcome and Introduction
03 June 2021 08:15 - 08:20 .ics
Receptor or ligand? Discussing pro's and con's in IL-6 inhibition
03 June 2021 08:20 - 08:35 .ics
Safety and efficacy of olokizumab in MTX-IR and TNF-IR in CREDO program
03 June 2021 08:35 - 08:50 .ics
“Difficult to treat RA” – definitions and therapeutic prospects: is there a place for olokizumab?”
03 June 2021 08:50 - 09:05 .ics
Reflections on EULAR RA management recommendations: takeaways for translation into clinical practice
03 June 2021 09:05 - 09:20 .ics
Panel discussion and close of meeting
03 June 2021 09:20 - 09:45 .ics